瑞财经 吴文婷11月12日,浙江时迈药业股份有限公司(以下简称“时迈药业”)在港交所递交招股书,独家保荐人为华泰国际。时迈药业成立于2017年,是下一代T细胞衔接器(TCE)疗法的先驱及企业。TCE为双特异性或多特异性抗体,其设计原理是通过同时结合肿瘤细胞上的肿瘤相关抗原(TAA)及T细胞上的受体,从而定向至肿瘤组织并激活T细胞,以诱导靶向细胞毒性作用。据招股书,2023年-2024年,时迈药业...
Source Link瑞财经 吴文婷11月12日,浙江时迈药业股份有限公司(以下简称“时迈药业”)在港交所递交招股书,独家保荐人为华泰国际。时迈药业成立于2017年,是下一代T细胞衔接器(TCE)疗法的先驱及企业。TCE为双特异性或多特异性抗体,其设计原理是通过同时结合肿瘤细胞上的肿瘤相关抗原(TAA)及T细胞上的受体,从而定向至肿瘤组织并激活T细胞,以诱导靶向细胞毒性作用。据招股书,2023年-2024年,时迈药业...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.